MedTrace Logo

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

NCT01864538 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-05-11

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.

Conditions

Interventions

DRUG

TH-302

480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.

Sponsors & Collaborators

  • ImmunoGenesis

    lead INDUSTRY

Principal Investigators

  • Tillman Pearce, MD · Threshold Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01864538 on ClinicalTrials.gov